- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05397431
A Survey of Lanadelumab in Participants With Hereditary Angioedema
Specific Use-Results Survey of TAKHZYRO Subcutaneous Injection 300 mg Syringe for Hereditary Angioedema With Long-term Administration
This study is a survey in Japan of Lanadelumab used to treat people with hereditary angioedema (HAE). The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.
The main aim of the study is to check for side effects related from Lanadelumab and to check if Lanadelumab improves symptoms of HAE. During the study, participants with HAE will take Lanadelumab subcutaneous injection according to their clinic's standard practice. The study doctors will check for side effects from Lanadelumab for 12 months.
Study Overview
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Takeda Contact
- Phone Number: +1-877-825-3327
- Email: medinfoUS@takeda.com
Study Locations
-
-
T
-
Tokyo, T, Japan
- Recruiting
- Takeda selected site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria - Participants diagnosed with hereditary angioedema (HAE) and treated with Lanadelumab for the first time.
Exclusion Criteria
- None
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Lanadelumab
Participants will receive 300 milligram (mg) of Lanadelumab Subcutaneous (SC) injection once every 2 weeks.
|
Lanadelumab 300 mg, subcutaneous injection every 2 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Who Experienced At Least One Treatment-Emergent Adverse Event (TEAE)
Time Frame: 12 Months
|
An adverse event (AE) is any untoward medical occurrence in a patient administered a medicinal product.
An adverse event does not necessarily have a causal relationship with the intervention.
An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.
|
12 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Angioedema Attacks
Time Frame: 12 Months
|
Number of angioedema attacks during the study will be assessed.
|
12 Months
|
Angioedema Quality of life (AE-QoL) Questionnaire
Time Frame: 12 Months
|
The AE-QoL questionnaire is a self-administered validated instrument to assess health related (HR)QoL among participants with recurrent angioedema (including HAE).
The AE-QoL consists of 17 disease-specific quality-of-life items, to produce a total AE-QoL score and 4 domain scores (functioning, fatigue/mood, fear/shame, and nutrition) and each of the 17 items has a five-point response scale ranging from 1 (Never) to 5 (Very Often).
|
12 Months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Study Director, Takeda
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Skin Diseases
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Hypersensitivity, Immediate
- Genetic Diseases, Inborn
- Skin Diseases, Vascular
- Hypersensitivity
- Urticaria
- Hereditary Complement Deficiency Diseases
- Primary Immunodeficiency Diseases
- Angioedema
- Angioedemas, Hereditary
Other Study ID Numbers
- TAK-743-4004
- jRCT2031220105 (Registry Identifier: jRCT)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hereditary Angioedema (HAE)
-
CENTOGENE GmbH RostockCompletedHereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | C1 Esterase Inhibitor Deficiency | HAE | Angio Edema | C4 Deficiency | Hereditary Angioedema Type IIITurkey, Armenia, Georgia, India, Peru, Poland, Romania
-
TakedaNot yet recruitingHereditary Angioedema (HAE)
-
CSL BehringRecruitingHereditary Angioedema (HAE)United States, Israel
-
TakedaRecruitingHereditary Angioedema (HAE)United Kingdom
-
TakedaRecruitingHereditary Angioedema (HAE)Poland
-
ShireTakeda Development Center Americas, Inc.RecruitingHereditary Angioedema (HAE)France, Austria, Australia, Spain, Czechia, Italy, United Kingdom, Germany, Israel, Ireland, Brazil, Denmark, Greece, Sweden
-
ShireTakeda Development Center Americas, Inc.CompletedHereditary Angioedema (HAE)Canada, United States, Puerto Rico
-
TakedaCompletedHereditary Angioedema (HAE)France, Germany, Austria, Greece
-
ShireCompletedHereditary Angioedema (HAE)United States, Jordan, Canada
-
ShireDyax Corp.CompletedHereditary Angioedema (HAE)United States, Canada, Germany, Italy, Jordan, Puerto Rico, United Kingdom
Clinical Trials on Lanadelumab
-
TakedaCompletedHereditary Angioedema (HAE)China
-
Radboud University Medical CenterTakedaCompleted
-
TakedaTakeda Development Center Americas, Inc.Completed
-
ShireCompleted
-
ShireCompletedHereditary AngioedemaUnited States, Canada, Germany, Hungary, Spain
-
ShireTakeda Development Center Americas, Inc.WithdrawnCOVID-19 Pneumonia
-
ShireCompletedHealthy VolunteersUnited States
-
ShireTakeda Development Center Americas, Inc.No longer availableAngioedema | Hereditary Angioedema (HAE)United States, Canada, Germany, Hungary, Spain
-
Vanderbilt University Medical CenterRecruitingHemodialysis Complication | Hypotension of HemodialysisUnited States
-
Charite University, Berlin, GermanyShire International GmbHActive, not recruitingHereditary Autoinflammatory DiseaseGermany